Tag: lobularBreastCancer

Articles

• Breast cancer types
• Foods to eat and avoid for lobular breast cancer patients & survivors
• Lobular breast cancer and LCIS characteristics
• Lobular breast cancer prognosis
• Lobular breast cancer recurrence & survival data

News

03/16/14

Over 80% of women diagnosed with DCIS or LCIS do not progress

06/25/12

Lobular breast cancer has less favorable prognosis than expected

05/24/12

Multifocal breast cancer is treated less successfully than unifocal

12/04/11

Lumpectomy vs. mastectomy rates vary by type of breast cancer

09/07/11

Strongly ER+ lobular breast cancer responds well to Femara

11/04/10

MRIs find additional disease in 20% of lobular BC patients

10/03/10

Lobular breast cancer micrometastases may be classified incorrectly

Studies

• Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis Cite
  Alkhafaji S, Wolf DM, Magbanua MJM, J. van ‘t Veer L, Park JW, Esserman L, et al. Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis. npj Breast Cancer. Springer Science and Business Media LLC; 2024; 10 10.1038/s41523-024-00623-9
• Molecular and clinical portrait of HER2-low invasive lobular carcinomas Cite
  Djerroudi L, El Sabeh-Ayoun A, Benoist C, Pierron G, Masliah-Planchon J, Fuhrmann L, et al. Molecular and clinical portrait of HER2-low invasive lobular carcinomas. Modern Pathology. Elsevier BV; 2024;:100463 10.1016/j.modpat.2024.100463
• Male Invasive Lobular Breast Cancer: Clinicopathologic Features Including Recurrence Score Results From a Population-Based Database Cite
  Balatico M, Ruano AL, Cleary AS, Lomo L, Gulbahce HE. Male Invasive Lobular Breast Cancer: Clinicopathologic Features Including Recurrence Score Results From a Population-Based Database. Archives of Pathology & Laboratory Medicine. Archives of Pathology and Laboratory Medicine; 2024; 148:263-264 10.5858/arpa.2023-0364-le
• Comparison of clinicopathologic characteristics and survival outcomes of various subtypes of breast cancer Cite
  Zangouri V, Balaneji SS, Deylami I, Zeinalpor A, Mousavi SA, Amestejani M. Comparison of clinicopathologic characteristics and survival outcomes of various subtypes of breast cancer. Research Square Platform LLC; 2024; 10.21203/rs.3.rs-3890579/v1
• Metastatic Profiles and Survival Differences Between Infiltrating Ductal Carcinoma and Infiltrating Lobular Carcinoma in Invasive Breast Cancer Cite
  CAVALLER L, GOUPILLE C, ARBION F, VILDE A, BODY G, OULDAMER L. Metastatic Profiles and Survival Differences Between Infiltrating Ductal Carcinoma and Infiltrating Lobular Carcinoma in Invasive Breast Cancer. Journal of Gynecology Obstetrics and Human Reproduction. Elsevier BV; 2024;:102740 10.1016/j.jogoh.2024.102740
• The effect of (neo)adjuvant chemotherapy on long‐term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study Cite
  Öztekin S, Hooning MJ, van Deurzen CHM, Dietvorst AHP, Drooger JC, Kitzen JJEM, et al. The effect of (neo)adjuvant chemotherapy on long‐term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study. Cancer. Wiley; 2023; 10.1002/cncr.35125
• Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: results from the SUCCESS trials Cite
  Dayan D, Lukac S, Rack B, Ebner F, Fink V, Leinert E, et al. Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: results from the SUCCESS trials. Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01750-0
• Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy Cite
  Rothschild HT, Clelland EN, Mujir F, Record H, Wong J, Esserman LJ, et al. Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 30:5999-6006 10.1245/s10434-023-13881-x
• Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer Cite
  Göker M, Denys H, Hendrix A, De Wever O, Van de Vijver K, Braems G. Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer. Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01745-x
• Survival Outcomes in Premenopausal Patients With Invasive Lobular Carcinoma Cite
  Yoon TI, Jeong J, Lee S, Ryu JM, Lee YJ, Lee JY, et al. Survival Outcomes in Premenopausal Patients With Invasive Lobular Carcinoma. JAMA Network Open. American Medical Association (AMA); 2023; 6:e2342270 10.1001/jamanetworkopen.2023.42270
• Tumor Characteristics of Bilateral Breast Cancer Compared with Unilateral Breast Cancer Cite
  Schulze AK, Hoskin TL, Moldoveanu D, Sturz JL, Boughey JC. Tumor Characteristics of Bilateral Breast Cancer Compared with Unilateral Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-14451-x
• Lobular-Like Features and Outcomes of Mixed Invasive Ductolobular Breast Cancer (MIDLC): Insights from 54,403 Stage I–III MIDLC Patients Cite
  Lohani KR, Hoskin TL, Day CN, Yasir S, Boughey JC, Degnim AC. Lobular-Like Features and Outcomes of Mixed Invasive Ductolobular Breast Cancer (MIDLC): Insights from 54,403 Stage I–III MIDLC Patients. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-14455-7
• THU477 Drivers Of Estrogen Induced Invasive Lobular Carcinoma Cite
  Ufondu C, Clem L, Musick M, Sikora MJ, Ostrander JH. THU477 Drivers Of Estrogen Induced Invasive Lobular Carcinoma. Journal of the Endocrine Society. The Endocrine Society; 2023; 7 10.1210/jendso/bvad114.2105
• Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics Cite
  Gamble LA, McClelland PH, Teke ME, Samaranayake SG, Juneau P, Famiglietti AL, et al. Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics. npj Breast Cancer. Springer Science and Business Media LLC; 2023; 9 10.1038/s41523-023-00585-4
• Prognostic value of axillary lymph node metastases in invasive lobular breast carcinoma Cite
  DEBERTI M, GOUPILLE C, ARBION F, VILDE A, BODY G, OULDAMER L. Prognostic value of axillary lymph node metastases in invasive lobular breast carcinoma. Journal of Gynecology Obstetrics and Human Reproduction. Elsevier BV; 2023;:102665 10.1016/j.jogoh.2023.102665
• Clinical characteristics and treatment outcomes of invasive ductal and lobular carcinoma: analyses of 54,832 taiwan cancer registry index cases Cite
  Chen B, Tsai Y, Lien P, Lin Y, Feng C, Chen Y, et al. Clinical characteristics and treatment outcomes of invasive ductal and lobular carcinoma: analyses of 54,832 taiwan cancer registry index cases. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 201:547-560 10.1007/s10549-023-07044-5
• Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes Cite
  Kaur M, Patterson A, Molina-Vega J, Rothschild H, Clelland E, Ewing CA, et al. Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes. Cancer Epidemiology, Biomarkers & Prevention. American Association for Cancer Research (AACR); 2023; 32:1107-1113 10.1158/1055-9965.epi-22-1353
• Carvacrol-Fabricated Chitosan Nanoparticle Synergistic Potential with Topoisomerase Inhibitors on Breast and Cervical Cancer Cells Cite
  Akhlaq A, Ashraf M, Omer MO, Altaf I. Carvacrol-Fabricated Chitosan Nanoparticle Synergistic Potential with Topoisomerase Inhibitors on Breast and Cervical Cancer Cells. ACS Omega. American Chemical Society (ACS); 2023; 10.1021/acsomega.3c03337
• Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment Cite
  Ramalingam K, Clelland E, Rothschild H, Mujir F, Record H, Kaur M, et al. Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-14075-1
• Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes Cite
  Clelland EN, Rothschild HT, Patterson A, Molina-Vega J, Kaur M, Symmans WF, et al. Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07059-y
• Is Choosing Wisely Wise for Lobular Carcinoma in Patients Over 70 Years of Age? A National Cancer Database Analysis of Sentinel Node Practice Patterns Cite
  Goldhaber NH, O’Keefe T, Kang J, Douglas S, Blair SL. Is Choosing Wisely Wise for Lobular Carcinoma in Patients Over 70 Years of Age? A National Cancer Database Analysis of Sentinel Node Practice Patterns. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-13886-6
• Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry Cite
  Adachi Y, Asaga S, Kumamaru H, Kinugawa N, Sagara Y, Niikura N, et al. Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07022-x
• Absence of Lobular Carcinoma In Situ is a Poor Prognostic Marker in Invasive Lobular Carcinoma Cite
  Mouabbi JA, Raghavendra AS, Bassett RL, Christgen M, Middleton L, Teshome M, et al. Absence of Lobular Carcinoma In Situ is a Poor Prognostic Marker in Invasive Lobular Carcinoma. European Journal of Cancer. Elsevier BV; 2023;:113250 10.1016/j.ejca.2023.113250
• ASO Author Reflections: Patient, Tumor, and Treatment Characteristics Predict Early Versus Late Recurrence in Patients with Invasive Lobular Carcinoma of the Breast Cite
  Rothschild HT, Mukhtar RA. ASO Author Reflections: Patient, Tumor, and Treatment Characteristics Predict Early Versus Late Recurrence in Patients with Invasive Lobular Carcinoma of the Breast. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-13909-2
• Classifying invasive lobular carcinoma as special type breast cancer may be reducing its treatment success: A comparison of survival among invasive lobular carcinoma, invasive ductal carcinoma, and no-lobular special type breast cancer Cite
  Cosar R, Sut N, Topaloglu S, Tastekin E, Nurlu D, Ozler T, et al. Classifying invasive lobular carcinoma as special type breast cancer may be reducing its treatment success: A comparison of survival among invasive lobular carcinoma, invasive ductal carcinoma, and no-lobular special type breast cancer. PLOS ONE. Public Library of Science (PLoS); 2023; 18:e0283445 10.1371/journal.pone.0283445
• 62P KI67 in ER+HER2-negative pure invasive lobular breast carcinoma (ILC). What’s the best Ki67 threshold to differentiate prognosis? Cite
  Bellet-Ezquerra M, Pardo PG, Fasani R, Villacampa G, Portu M, Serna G, et al. 62P KI67 in ER+HER2-negative pure invasive lobular breast carcinoma (ILC). What’s the best Ki67 threshold to differentiate prognosis?. ESMO Open. Elsevier BV; 2023; 8:101286 10.1016/j.esmoop.2023.101286
• 254P The invasive lobular cancer of the breast (ILC): A collection of clinical and pathological data in patients with (non-)metastatic breast cancer (BC) Cite
  Ljubicic T, Pross T, Dordevic A, Röhle R, Gebert P, Jank P, et al. 254P The invasive lobular cancer of the breast (ILC): A collection of clinical and pathological data in patients with (non-)metastatic breast cancer (BC). ESMO Open. Elsevier BV; 2023; 8:101442 10.1016/j.esmoop.2023.101442
• Management of Lobular Neoplasia Diagnosed by Core Biopsy Cite
  Jani C, Lotz M, Keates S, Gupta Y, Walker A, Al Omari O, et al. Management of Lobular Neoplasia Diagnosed by Core Biopsy. The Breast Journal. Hindawi Limited; 2023; 2023:1-9 10.1155/2023/8185446
• Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015) Cite
  Bliss JM, Tovey H, Evans A, Holcombe C, Horgan K, Mallon E, et al. Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015). Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01626-3
• Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases Cite
  Trillo P, Sandoval J, Trapani D, Nicolò E, Zagami P, Giugliano F, et al. Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases. European Journal of Cancer. Elsevier BV; 2023; 185:119-130 10.1016/j.ejca.2023.02.028
• Evolution of biological features of invasive lobular breast cancer: comparison between primary tumor and metastases Cite
  Aliaga PT, Sandoval J, Trapani D, Nicolò E, Zagami P, Giugliano F, et al. Evolution of biological features of invasive lobular breast cancer: comparison between primary tumor and metastases. European Journal of Cancer. Elsevier BV; 2023; 10.1016/j.ejca.2023.02.028
• Invasive Lobular Carcinoma: A Review of Imaging Modalities with Special Focus on Pathology Concordance Cite
  Pereslucha AM, Wenger DM, Morris MF, Aydi ZB. Invasive Lobular Carcinoma: A Review of Imaging Modalities with Special Focus on Pathology Concordance. Healthcare. MDPI AG; 2023; 11:746 10.3390/healthcare11050746
• Abstract P3-05-08: Prevalence and prognosis of ER-loss in advanced invasive lobular carcinoma Cite
  Hensing WL, Xiu J, Korn WM, Graff SL, Kang I, Torres ETR, et al. Abstract P3-05-08: Prevalence and prognosis of ER-loss in advanced invasive lobular carcinoma. Cancer Research. American Association for Cancer Research (AACR); 2023; 83:P3-05-08-P3-05-08 10.1158/1538-7445.sabcs22-p3-05-08
• HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study Cite
  kada Mohammed S, Billa O, Ladoire S, Jankowski C, Desmoulins I, Poillot M, et al. HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study. Breast Cancer. Springer Science and Business Media LLC; 2023; 10.1007/s12282-022-01432-3
• Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma Cite
  Nasrazadani A, Li Y, Fang Y, Shah O, Atkinson JM, Lee JS, et al. Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma. British Journal of Cancer. Springer Science and Business Media LLC; 2023; 10.1038/s41416-022-02131-8
• Invasive Lobular Carcinoma of the Breast: Toward Tailoring Therapy? Cite
  Djerroudi L, Cabel L, Bidard F, Vincent-Salomon A. Invasive Lobular Carcinoma of the Breast: Toward Tailoring Therapy?. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2022; 114:1434-1436 10.1093/jnci/djac159
• Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction Cite
  KUBOTA Y, HAN Q, MASAKI N, HOZUMI C, HAMADA K, AOKI Y, et al. Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction. Anticancer Research. Anticancer Research USA Inc.; 2022; 42:5819-5823 10.21873/anticanres.16089
• Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer Cite
  Oesterreich S, Nasrazadani A, Zou J, Carleton N, Onger T, Wright MD, et al. Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2022; 10.1093/jnci/djac157
• Biomarker profile of invasive lobular carcinoma: pleomorphic versus classic subtypes, clinicopathological characteristics and prognosis analyses Cite
  Zhang Y, Luo X, Chen M, Yang L, Lei T, Pu T, et al. Biomarker profile of invasive lobular carcinoma: pleomorphic versus classic subtypes, clinicopathological characteristics and prognosis analyses. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 194:279-295 10.1007/s10549-022-06627-y
• Risk of contralateral breast and other cancers in patients with invasive lobular breast cancer. Cite
  Choong GMY, Savitz ST, Giridhar K, Haddad TC, Ruddy KJ, Boughey JC, et al. Risk of contralateral breast and other cancers in patients with invasive lobular breast cancer.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 40:555-555 10.1200/jco.2022.40.16_suppl.555
• Diagnostic Challenge of Invasive Lobular Carcinoma of the Breast: What Is the News? Breast Magnetic Resonance Imaging and Emerging Role of Contrast-Enhanced Spectral Mammography Cite
  Costantini M, Montella RA, Fadda MP, Tondolo V, Franceschini G, Bove S, et al. Diagnostic Challenge of Invasive Lobular Carcinoma of the Breast: What Is the News? Breast Magnetic Resonance Imaging and Emerging Role of Contrast-Enhanced Spectral Mammography. Journal of Personalized Medicine. MDPI AG; 2022; 12:867 10.3390/jpm12060867
• Identification of a 5-gene-risk score model for predicting luminal A-invasive lobular breast cancer survival Cite
  Chen Y, Zhang T, Liu Y, Zheng J, Lin W, Chen Y, et al. Identification of a 5-gene-risk score model for predicting luminal A-invasive lobular breast cancer survival. Genetica. Springer Science and Business Media LLC; 2022; 10.1007/s10709-022-00157-7
• Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21‐gene recurrence score: A National Cancer Database analysis Cite
  Weiser R, Polychronopoulou E, Hatch SS, Haque W, Ghani HA, He J, et al. Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21‐gene recurrence score: A National Cancer Database analysis. Cancer. Wiley; 2022; 128:1738-1747 10.1002/cncr.34127
• The association between the inflammatory potential of diet and the risk of histopathological and molecular subtypes of breast cancer in northwestern Iran: Results from the Breast Cancer Risk and Lifestyle study Cite
  Hayati Z, Montazeri V, Shivappa N, Hebert JR, Pirouzpanah S. The association between the inflammatory potential of diet and the risk of histopathological and molecular subtypes of breast cancer in northwestern Iran: Results from the Breast Cancer Risk and Lifestyle study. Cancer. Wiley; 2022; 10.1002/cncr.34183
• A review on the added value of whole-body MRI in metastatic lobular breast cancer Cite
  Bhaludin BN, Tunariu N, Koh D, Messiou C, Okines AF, McGrath SE, et al. A review on the added value of whole-body MRI in metastatic lobular breast cancer. European Radiology. Springer Science and Business Media LLC; 2022; 10.1007/s00330-022-08714-6
• Adherence to a western dietary pattern and risk of invasive ductal and lobular breast carcinomas: a case–control study Cite
  Foroozani E, Akbari A, Amanat S, Rashidi N, Bastam D, Ataee S, et al. Adherence to a western dietary pattern and risk of invasive ductal and lobular breast carcinomas: a case–control study. Scientific Reports. Springer Science and Business Media LLC; 2022; 12 10.1038/s41598-022-09725-5
• Abstract PD14-08: Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status Cite
  Hills RK, Oesterreich S, Metzger O, Dabbs D, Pan H, Braybrooke J, et al. Abstract PD14-08: Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status. Cancer Research. American Association for Cancer Research (AACR); 2022; 82:PD14-08-PD14-08 10.1158/1538-7445.sabcs21-pd14-08
• Abstract PD14-06: Does chemotherapy benefit patients with HR+/HER2- invasive lobular breast cancer? Cite
  Yaghi M, Jabbal I, Bilani N, Zerdan MB, Elson L, Li H, et al. Abstract PD14-06: Does chemotherapy benefit patients with HR+/HER2- invasive lobular breast cancer?. Cancer Research. American Association for Cancer Research (AACR); 2022; 82:PD14-06-PD14-06 10.1158/1538-7445.sabcs21-pd14-06
• Vitamin D and Histological Features of Breast Cancer: Preliminary Data from an Observational Retrospective Italian Study Cite
  Lello S, Capozzi A, Scardina L, Ionta L, Sorge R, Scambia G, et al. Vitamin D and Histological Features of Breast Cancer: Preliminary Data from an Observational Retrospective Italian Study. Journal of Personalized Medicine. MDPI AG; 2022; 12:465 10.3390/jpm12030465
• Prognostic Significance of Lobular Carcinoma In-Situ (LCIS) Diagnosed Alongside Invasive Breast Cancer Cite
  Braasch MC, Amin AL, Balanoff CR, Wagner JL, Larson KE. Prognostic Significance of Lobular Carcinoma In-Situ (LCIS) Diagnosed Alongside Invasive Breast Cancer. Breast Cancer: Basic and Clinical Research. SAGE Publications; 2022; 16:117822342110702 10.1177/11782234211070217
• Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study Cite
  Dalenc F, Lusque A, De La Motte Rouge T, Pistilli B, Brain E, Pasquier D, et al. Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study. European Journal of Cancer. Elsevier BV; 2022; 164:70-79 10.1016/j.ejca.2021.12.031
• Lobular Carcinoma of the Breast Metastatic to the Ovary Cite
  Chuang A, Watkins JC, Young RH, Lerwill MF. Lobular Carcinoma of the Breast Metastatic to the Ovary. American Journal of Surgical Pathology. Ovid Technologies (Wolters Kluwer Health); 2021; 46:179-189 10.1097/pas.0000000000001812
• Clinical Characteristics and Survival Outcomes of Infiltrating Lobular Carcinoma: A Retrospective Study of 365 Cases in China Cite
  Han B, Gu Z, Liu Z, Ling H. Clinical Characteristics and Survival Outcomes of Infiltrating Lobular Carcinoma: A Retrospective Study of 365 Cases in China. Cancer Management and Research. Informa UK Limited; 2022; Volume 14:647-658 10.2147/cmar.s346319
• The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study Cite
  Abel MK, Shui AS, Chien AJ, Rugo HS, Melisko M, Baehner F, et al. The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study. Research Square Platform LLC; 2022; 10.21203/rs.3.rs-1322653/v1
• Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience Cite
  Okines A, Irfan T, Asare B, Mohammed K, Osin P, Nerurkar A, et al. Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-021-06432-z
• Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21‐gene recurrence score: A National Cancer Database analysis Cite
  Weiser R, Polychronopoulou E, Hatch SS, Haque W, Ghani HA, He J, et al. Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21‐gene recurrence score: A National Cancer Database analysis. Cancer. Wiley; 2022; 10.1002/cncr.34127
• Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations Cite
  Bergeron A, MacGrogan G, Bertaut A, Ladoire S, Arveux P, Desmoulins I, et al. Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations. Modern Pathology. Springer Science and Business Media LLC; 2021; 34:1282-1296 10.1038/s41379-021-00742-9
• Survival analysis in patients with invasive lobular cancer and invasive ductal cancer according to hormone receptor expression status in the Korean population Cite
  Kwon D, Ko BK, Jung SP, Kim H, Kim E, Jung YS, et al. Survival analysis in patients with invasive lobular cancer and invasive ductal cancer according to hormone receptor expression status in the Korean population. PLOS ONE. Public Library of Science (PLoS); 2022; 17:e0262709 10.1371/journal.pone.0262709
• Clinical Differences between Invasive Lobular Breast Cancer and Invasive Carcinoma of No Special Type in the German Mammography-Screening-Program Cite
  Farrokh A, Goldmann G, Meyer-Johann U, Hille-Betz U, Hillemanns P, Bader W, et al. Clinical Differences between Invasive Lobular Breast Cancer and Invasive Carcinoma of No Special Type in the German Mammography-Screening-Program. Women & Health. Informa UK Limited; 2022;:1-13 10.1080/03630242.2022.2030448
• The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study Cite
  Abel MK, Shui AM, Melisko M, Chien AJ, Yoshida EJ, Lancaster EM, et al. The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study. npj Breast Cancer. Springer Science and Business Media LLC; 2021; 7 10.1038/s41523-021-00366-x
• Impact of Preoperative MRI in Invasive Ductal Carcinoma With Lobular Features on Core Biopsy Cite
  Jafferbhoy SF, Goussous G, Chandarana M, Salehi-Bird S, Mohd-Isa Z, Gunning E, et al. Impact of Preoperative MRI in Invasive Ductal Carcinoma With Lobular Features on Core Biopsy. Clinical Breast Cancer. Elsevier BV; 2021; 21:e194-e198 10.1016/j.clbc.2020.08.007
• Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery–A systematic review and meta-analysis Cite
  O'Connor DJ, Davey MG, Barkley LR, Kerin MJ. Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery–A systematic review and meta-analysis. The Breast. Elsevier BV; 2022; 61:1-10 10.1016/j.breast.2021.11.017
• Palpable multifocal and multicentric invasive lobular breast carcinoma in a young female Cite
  Qiu W, Hu TN. Palpable multifocal and multicentric invasive lobular breast carcinoma in a young female. Radiology Case Reports. Elsevier BV; 2022; 17:269-274 10.1016/j.radcr.2021.10.056
• Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer Cite
  Rothschild HT, Abel MK, Patterson A, Goodman K, Shui A, van Baelen K, et al. Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06453-8
• Invasive Lobular Breast Cancer: Data to Support Surgical Decision Making Cite
  Cocco D, ElSherif A, Wright MD, Dempster MS, Kruse ML, Li H, et al. Invasive Lobular Breast Cancer: Data to Support Surgical Decision Making. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2021; 28:5723-5729 10.1245/s10434-021-10455-7
• AB009. SOH21AS214. Invasive lobular breast cancer—patterns of metastatic disease and survival Cite
  Finnegan L, McAnena P, O’Halloran N, Curran C, Lowery A, Kerin M. AB009. SOH21AS214. Invasive lobular breast cancer—patterns of metastatic disease and survival. Mesentery and Peritoneum. AME Publishing Company; 2021; 5:AB009-AB009 10.21037/map-21-ab009
• Expression of N-Terminal-Deficient E-Cadherin Protein in Invasive Lobular Carcinoma of the Breast Cite
  Yasui H, Kawata T, Muramatsu K, Kakuda Y, Oishi T, Norose T, et al. Expression of N-Terminal-Deficient E-Cadherin Protein in Invasive Lobular Carcinoma of the Breast. American Journal of Surgical Pathology. Ovid Technologies (Wolters Kluwer Health); 2021; Publish Ahead of Print 10.1097/pas.0000000000001822
• Association Between Hereditary Lobular Breast Cancer Due to CDH1 Variants and Gastric Cancer Risk Cite
  Gamble LA, Rossi A, Fasaye G, Kesserwan C, Hernandez JM, Blakely AM, et al. Association Between Hereditary Lobular Breast Cancer Due to CDH1 Variants and Gastric Cancer Risk. JAMA Surgery. American Medical Association (AMA); 2021; 10.1001/jamasurg.2021.5118
• 189P Invasive lobular carcinoma in young breast cancer patients: Incidence and clinicopathological characteristics Cite
  Omar A, Masoud H, Darwesh A. 189P Invasive lobular carcinoma in young breast cancer patients: Incidence and clinicopathological characteristics. Annals of Oncology. Elsevier BV; 2021; 32:S440 10.1016/j.annonc.2021.08.470
• The Real-world Outcomes of Patients With Advanced Invasive Lobular Carcinoma of the Breast Compared With Invasive Ductal Carcinoma: A Review at a Single Institution Cite
  WATANABE J, NAKAMOTO S, SUGINO T. The Real-world Outcomes of Patients With Advanced Invasive Lobular Carcinoma of the Breast Compared With Invasive Ductal Carcinoma: A Review at a Single Institution. Anticancer Research. Anticancer Research USA Inc.; 2021; 41:4619-4627 10.21873/anticanres.15275
• Clinicopathological features of and neoadjuvant therapy for HER2-positive classic invasive lobular carcinoma Cite
  Huang X, Chen H, Ding Q, Robinson MK, Moseley TW, Bassett IRL, et al. Clinicopathological features of and neoadjuvant therapy for HER2-positive classic invasive lobular carcinoma. Human Pathology. Elsevier BV; 2021; 10.1016/j.humpath.2021.07.010
• Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women Cite
  Evans DG, Howell SJ, Gandhi A, van Veen EM, Woodward ER, Harvey J, et al. Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06333-1
• Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up Cite
  Chamalidou C, Fohlin H, Albertsson P, Arnesson L, Einbeigi Z, Holmberg E, et al. Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up. The Breast. Elsevier BV; 2021; 10.1016/j.breast.2021.07.011
• Is axillary imaging for invasive lobular carcinoma accurate in determining clinical node staging? Cite
  Schumacher K, Inciardi M, O’Neil M, Wagner JL, Shah I, Amin AL, et al. Is axillary imaging for invasive lobular carcinoma accurate in determining clinical node staging?. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 185:567-572 10.1007/s10549-020-06047-w
• Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes Cite
  Hosio M, Urpilainen E, Hautakoski A, Marttila M, Arffman M, Sund R, et al. Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes. Scientific Reports. Springer Science and Business Media LLC; 2021; 11 10.1038/s41598-021-88488-x
• Oncological Outcomes of Total Skin-Sparing Mastectomy for Invasive Lobular Carcinoma of the Breast: A 20-Year Institutional Experience Cite
  Son JD, Piper M, Hewitt K, Alvarado M, Esserman LJ, Ewing C, et al. Oncological Outcomes of Total Skin-Sparing Mastectomy for Invasive Lobular Carcinoma of the Breast: A 20-Year Institutional Experience. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 28:2555-2560 10.1245/s10434-020-09042-z
• Invasive Lobular Carcinoma of the Breast: Ongoing Trials, Challenges, and Future Directions Cite
  Mukhtar RA, Chien AJ. Invasive Lobular Carcinoma of the Breast: Ongoing Trials, Challenges, and Future Directions. Current Breast Cancer Reports. Springer Science and Business Media LLC; 2021; 10.1007/s12609-021-00412-4
• Benefit of Adjuvant Chemotherapy in Patients with Lobular Breast Cancer: a Systematic Review of the Literature and Metanalysis Cite
  Trapani D, Gandini S, Corti C, Crimini E, Bellerba F, Minchella I, et al. Benefit of Adjuvant Chemotherapy in Patients with Lobular Breast Cancer: a Systematic Review of the Literature and Metanalysis. Cancer Treatment Reviews. Elsevier BV; 2021;:102205 10.1016/j.ctrv.2021.102205
• Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: a nationwide data linkage study Cite
  Feng J, Qin X. Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: a nationwide data linkage study. Diabetes Research and Clinical Practice. Elsevier BV; 2021;:108755 10.1016/j.diabres.2021.108755
• The lobular neoplasia enigma: management and prognosis in a long follow-up case series Cite
  Metovic J, Abate SO, Borella F, Vissio E, Bertero L, Mariscotti G, et al. The lobular neoplasia enigma: management and prognosis in a long follow-up case series. World Journal of Surgical Oncology. Springer Science and Business Media LLC; 2021; 19 10.1186/s12957-021-02182-w
• Invasive lobular carcinoma of the breast: the increasing importance of this special subtype Cite
  McCart Reed AE, Kalinowski L, Simpson PT, Lakhani SR. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast Cancer Research. Springer Science and Business Media LLC; 2021; 23 10.1186/s13058-020-01384-6
• Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma Cite
  Segar JM, Pandey R, Farr KJ, Nagle R, LeBeau L, Gonzalez VJ, et al. Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma. International Journal of Breast Cancer. Hindawi Limited; 2020; 2020:1-7 10.1155/2020/8816824
• A nomogram for determining the disease-specific survival in invasive lobular carcinoma of the breast Cite
  Fu R, Yang J, Wang H, Li L, Kang Y, Kaaya RE, et al. A nomogram for determining the disease-specific survival in invasive lobular carcinoma of the breast. Medicine. Ovid Technologies (Wolters Kluwer Health); 2020; 99:e22807 10.1097/md.0000000000022807
• Dietary Patterns and Risk of Invasive Ductal and Lobular Breast Carcinomas: A Systematic Review and Meta-analysis Cite
  Dianatinasab M, Rezaian M, HaghighatNezad E, Bagheri-Hosseinabadi Z, Amanat S, Rezaeian S, et al. Dietary Patterns and Risk of Invasive Ductal and Lobular Breast Carcinomas: A Systematic Review and Meta-analysis. Clinical Breast Cancer. Elsevier BV; 2020; 20:e516-e528 10.1016/j.clbc.2020.03.007
• Triple-negative pleomorphic lobular carcinoma and expression of androgen receptor: Personal case series and review of the literature Cite
  Taniguchi K, Takada S, Omori M, Igawa T, Nishimura MF, Morito T, et al. Triple-negative pleomorphic lobular carcinoma and expression of androgen receptor: Personal case series and review of the literature. PLOS ONE. Public Library of Science (PLoS); 2020; 15:e0235790 10.1371/journal.pone.0235790
• The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast Cite
  Zhao H. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast. Breast Cancer. Springer Science and Business Media LLC; 2020; 10.1007/s12282-020-01146-4
• Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer Cite
  Christgen M, Gluz O, Harbeck N, Kates RE, Raap M, Christgen H, et al. Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer. Cancer. Wiley; 2020; 126:4847-4858 10.1002/cncr.33104
• Hereditary diffuse gastric cancer: updated clinical practice guidelines Cite
  Blair VR, McLeod M, Carneiro F, Coit DG, D'Addario JL, van Dieren JM, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. The Lancet Oncology. Elsevier BV; 2020; 21:e386-e397 10.1016/s1470-2045(20)30219-9
• Population Trends in Lobular Carcinoma of the Breast: The Ontario Experience Cite
  Findlay-Shirras LJ, Lima I, Smith G, Clemons M, Arnaout A. Population Trends in Lobular Carcinoma of the Breast: The Ontario Experience. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 27:4711-4719 10.1245/s10434-020-08895-8
• Hereditary Gastric and Breast Cancer Syndromes Related to CDH1 Germline Mutation: A Multidisciplinary Clinical Review Cite
  Corso G, Montagna G, Figueiredo J, La Vecchia C, Fumagalli Romario U, Fernandes MS, et al. Hereditary Gastric and Breast Cancer Syndromes Related to CDH1 Germline Mutation: A Multidisciplinary Clinical Review. Cancers. MDPI AG; 2020; 12:1598 10.3390/cancers12061598
• Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast. Cite
  Conforti F, Pala L, Guerini Rocco E, Pagan E, Bagnardi V, Montagna E, et al. Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:e12570-e12570 10.1200/jco.2020.38.15_suppl.e12570
• Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers Cite
  Corona SP, Bortul M, Scomersi S, Bigal C, Bottin C, Zanconati F, et al. Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:735-745 10.1007/s10549-020-05565-x
• Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence Cite
  Conforti F, Pala L, Pagan E, Viale G, Bagnardi V, Peruzzotti G, et al. Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. Breast Cancer Research. Springer Science and Business Media LLC; 2019; 21 10.1186/s13058-019-1234-9
• Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy Cite
  Luveta J, Parks RM, Heery DM, Cheung K, Johnston SJ. Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy. Oncology and Therapy. Springer Science and Business Media LLC; 2019; 8:1-11 10.1007/s40487-019-00105-0
• Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma Cite
  Thornton MJ, Williamson HV, Westbrook KE, Greenup RA, Plichta JK, Rosenberger LH, et al. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2019; 26:3166-3177 10.1245/s10434-019-07564-9
• Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers Cite
  Mamtani A, Zabor EC, Stempel M, Morrow M. Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2019; 26:3269-3274 10.1245/s10434-019-07536-z
• Why Breast Cancer Risk Models Fail: The Case of Lobular Carcinoma In Situ Cite
  Euhus DM. Why Breast Cancer Risk Models Fail: The Case of Lobular Carcinoma In Situ. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2019; 27:627-629 10.1245/s10434-019-07875-x
• Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast Cite
  Piper ML, Wong J, Fahrner-Scott K, Ewing C, Alvarado M, Esserman LJ, et al. Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast. npj Breast Cancer. Springer Science and Business Media LLC; 2019; 5 10.1038/s41523-019-0125-7
• The impact of chemotherapy sequence on survival in node‐positive invasive lobular carcinoma Cite
  Tamirisa N, Williamson HV, Thomas SM, Westbrook KE, Greenup RA, Plichta JK, et al. The impact of chemotherapy sequence on survival in node‐positive invasive lobular carcinoma. Journal of Surgical Oncology. Wiley; 2019; 10.1002/jso.25492
• E-cadherin clone 36 nuclear staining dictates adverse disease outcome in lobular breast cancer patients Cite
  Lobo J, Petronilho S, Newell AH, Coach J, Harlow G, Cruz A, et al. E-cadherin clone 36 nuclear staining dictates adverse disease outcome in lobular breast cancer patients. Modern Pathology. Springer Science and Business Media LLC; 2019; 32:1574-1586 10.1038/s41379-019-0294-9
• Long-term survival outcomes in invasive lobular carcinoma patients with and without preoperative MR imaging: a matched cohort study Cite
  Ha SM, Chae EY, Cha JH, Kim HH, Shin HJ, Choi WJ. Long-term survival outcomes in invasive lobular carcinoma patients with and without preoperative MR imaging: a matched cohort study. European Radiology. Springer Science and Business Media LLC; 2019; 29:2526-2534 10.1007/s00330-018-5952-7
• Clinical Outcomes in Triple-negative Lobular Breast Cancer: a Single-institution Experience Cite
  Irfan T, Turkes F, Asare B, Mohammed K, Osin P, Nerurkar A, et al. Clinical Outcomes in Triple-negative Lobular Breast Cancer: a Single-institution Experience. Clinical Oncology. Elsevier BV; 2019; 31:e110 10.1016/j.clon.2019.03.021
• Clinical Outcomes in HER2-positive Lobular Breast Cancer: a Single-institution Experience Cite
  Irfan T, Asare B, Mohammed K, Osin P, Nerurkar A, Smith I, et al. Clinical Outcomes in HER2-positive Lobular Breast Cancer: a Single-institution Experience. Clinical Oncology. Elsevier BV; 2019; 31:e109-e110 10.1016/j.clon.2019.03.020
• Breast cancer histologic subtypes show excess familial clustering Cite
  Henry NL, Cannon‐Albright LA. Breast cancer histologic subtypes show excess familial clustering. Cancer. Wiley; 2019; 125:3131-3138 10.1002/cncr.32198
• Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients Cite
  Flores-Díaz D, Arce C, Flores-Luna L, Reynoso-Noveron N, Lara-Medina F, Matus JA, et al. Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 176:243-249 10.1007/s10549-019-05234-8
• The effect of length of birth interval on the risk of breast cancer by subtype in grand multiparous women Cite
  Katuwal S, Tapanainen JS, Pukkala E, Kauppila A. The effect of length of birth interval on the risk of breast cancer by subtype in grand multiparous women. BMC Cancer. Springer Science and Business Media LLC; 2019; 19 10.1186/s12885-019-5404-z
• Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study Cite
  Wang K, Zhu G, Shi Y, Li Z, Zhang X, Li H. Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study. Clinical Breast Cancer. Elsevier BV; 2019; 19:e101-e115 10.1016/j.clbc.2018.10.010
• Outcomes of pleomorphic lobular carcinoma versus invasive lobular carcinoma Cite
  Haque W, Arms A, Verma V, Hatch S, Brian Butler E, Teh BS. Outcomes of pleomorphic lobular carcinoma versus invasive lobular carcinoma. The Breast. Elsevier BV; 2019; 43:67-73 10.1016/j.breast.2018.11.007
• No survival improvement of contralateral prophylactic mastectomy among women with invasive lobular carcinoma Cite
  Yu T, Liu Y, Hu X, Di G. No survival improvement of contralateral prophylactic mastectomy among women with invasive lobular carcinoma. Journal of Surgical Oncology. Wiley; 2018; 118:928-935 10.1002/jso.25221
• HER2 positive rates in invasive lobular breast carcinoma: A study amongst 1,095 consecutive Asian patients Cite
  Kee G, Tan R, Sultana R, Zaw M, Lian W, Tan K, et al. HER2 positive rates in invasive lobular breast carcinoma: A study amongst 1,095 consecutive Asian patients. Annals of Oncology. Elsevier BV; 2018; 29:ix1 10.1093/annonc/mdy426.002
• Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect Cite
  Corso G, Figueiredo J, La Vecchia C, Veronesi P, Pravettoni G, Macis D, et al. Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect. Journal of Medical Genetics. BMJ; 2018; 55:431-441 10.1136/jmedgenet-2018-105337
• Clinical criteria revision for hereditary lobular breast cancer associated with E-cadherin germline mutations Cite
  Corso G, De Scalzi A, Feroce I, Veronesi P, Bonanni B, Galimberti V. Clinical criteria revision for hereditary lobular breast cancer associated with E-cadherin germline mutations. Personalized Medicine. Future Medicine Ltd; 2018; 15:153-155 10.2217/pme-2017-0083
• Population-based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node-positive invasive lobular carcinoma of the breast Cite
  Morrow E, Lannigan A, Doughty J, Litherland J, Mansell J, Stallard S, et al. Population-based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node-positive invasive lobular carcinoma of the breast. British Journal of Surgery. Wiley; 2018; 105:987-995 10.1002/bjs.10791
• Incidence and tumour characteristics of bilateral and unilateral interval breast cancers at screening mammography Cite
  van Bommel RM, Voogd AC, Nederend J, Setz-Pels W, Louwman MW, Strobbe LJ, et al. Incidence and tumour characteristics of bilateral and unilateral interval breast cancers at screening mammography. The Breast. Elsevier BV; 2018; 38:101-106 10.1016/j.breast.2017.12.018
• Higher risk of metachronous contralateral breast cancer in patients with invasive lobular breast cancer Cite
  Akdeniz D, Kramer I, Van Deurzen C, Schaapveld M, Westenend P, Voogd A, et al. Higher risk of metachronous contralateral breast cancer in patients with invasive lobular breast cancer. European Journal of Cancer. Elsevier BV; 2018; 92:S46 10.1016/s0959-8049(18)30364-2
• Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27 Cite
  Strasser-Weippl K, Sudan G, Ramjeesingh R, Shepherd L, O'Shaughnessy J, Parulekar W, et al. Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. European Journal of Cancer. Elsevier BV; 2018; 90:19-25 10.1016/j.ejca.2017.11.014
• Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study Cite
  Mullooly M, Khodr ZG, Dallal CM, Nyante SJ, Sherman ME, Falk R, et al. Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study. American Journal of Epidemiology. Oxford University Press (OUP); 2017; 186:1329-1340 10.1093/aje/kwx206
• Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study Cite
  Williams LA, Nichols HB, Hoadley KA, Tse CK, Geradts J, Bell ME, et al. Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. Cancer Causes & Control. Springer Science and Business Media LLC; 2017; 29:25-32 10.1007/s10552-017-0977-9
• Neoadjuvant systemic therapy in invasive lobular breast cancer: Is it indicated? Cite
  Tsung K, Grobmyer SR, Tu C, Abraham J, Budd GT, Valente SA. Neoadjuvant systemic therapy in invasive lobular breast cancer: Is it indicated?. The American Journal of Surgery. Elsevier BV; 2018; 215:509-512 10.1016/j.amjsurg.2017.11.011
• Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma Cite
  Chen Z, Yang J, Li S, Lv M, Shen Y, Wang B, et al. Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma. PLOS ONE. Public Library of Science (PLoS); 2017; 12:e0182397 10.1371/journal.pone.0182397
• Breast cancer risk associated with atypical hyperplasia and lobular carcinoma in situ initially diagnosed on core-needle biopsy Cite
  Donaldson AR, McCarthy C, Goraya S, Pederson HJ, Sturgis CD, Grobmyer SR, et al. Breast cancer risk associated with atypical hyperplasia and lobular carcinoma in situ initially diagnosed on core-needle biopsy. Cancer. Wiley; 2017; 124:459-465 10.1002/cncr.31061
• Mixed invasive ductal and lobular carcinoma has distinct clinical features and predicts worse prognosis when stratified by estrogen receptor status Cite
  Xiao Y, Ma D, Ruan M, Zhao S, Liu X, Jiang Y, et al. Mixed invasive ductal and lobular carcinoma has distinct clinical features and predicts worse prognosis when stratified by estrogen receptor status. Scientific Reports. Springer Science and Business Media LLC; 2017; 7 10.1038/s41598-017-10789-x
• Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy Cite
  Petruolo OA, Pilewskie M, Patil S, Barrio AV, Stempel M, Wen HY, et al. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2017; 24:2556-2562 10.1245/s10434-017-5898-z
• Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes Cite
  Montagna E, Pirola S, Maisonneuve P, De Roberto G, Cancello G, Palazzo A, et al. Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes. Clinical Breast Cancer. Elsevier BV; 2018; 18:e401-e405 10.1016/j.clbc.2017.07.003
• Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes Cite
  Montagna E, Pirola S, Maisonneuve P, De Roberto G, Cancello G, Palazzo A, et al. Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes. Clinical Breast Cancer. Elsevier BV; 2018; 18:e401-e405 10.1016/j.clbc.2017.07.003
• Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population Cite
  Reiner AS, Lynch CF, Sisti JS, John EM, Brooks JD, Bernstein L, et al. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population. Breast Cancer Research. Springer Science and Business Media LLC; 2017; 19 10.1186/s13058-017-0874-x
• Distinct Pattern of Metastases in Patients with Invasive Lobular Carcinoma of the Breast Cite
  Mathew A, Rajagopal P, Villgran V, Sandhu G, Jankowitz R, Jacob M, et al. Distinct Pattern of Metastases in Patients with Invasive Lobular Carcinoma of the Breast. Geburtshilfe und Frauenheilkunde. Georg Thieme Verlag KG; 2017; 77:660-666 10.1055/s-0043-109374
• Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast Cite
  Kizy S, Huang JL, Marmor S, Tuttle TM, Hui JYC. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 165:757-763 10.1007/s10549-017-4355-9
• Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study Cite
  Mullooly M, Khodr ZG, Dallal CM, Nyante SJ, Sherman ME, Falk R, et al. Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study. American Journal of Epidemiology. Oxford University Press (OUP); 2017; 186:1329-1340 10.1093/aje/kwx206
• Alcohol Intake and Risk of Breast Cancer by Histologic Subtype and Estrogen Receptor Status Among Women Aged 55 to 74 Years Cite
  Baglia ML, Malone KE, Tang MC, Li CI. Alcohol Intake and Risk of Breast Cancer by Histologic Subtype and Estrogen Receptor Status Among Women Aged 55 to 74 Years. Hormones and Cancer. Springer Science and Business Media LLC; 2017; 8:211-218 10.1007/s12672-017-0297-2
• (S042) Invasive Lobular Carcinoma Predicts for an Increased Likelihood of Surgical Upstaging Requiring Post-Mastectomy Radiation Therapy Cite
  Van Wyhe RD, Shaitelman SF, Caudle AS, Hoffman KE, Perkins GH, Tereffe W, et al. (S042) Invasive Lobular Carcinoma Predicts for an Increased Likelihood of Surgical Upstaging Requiring Post-Mastectomy Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2017; 98:E13 10.1016/j.ijrobp.2017.02.078
• Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast Cite
  Marmor S, Hui JYC, Huang JL, Kizy S, Beckwith H, Blaes AH, et al. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast. Cancer. Wiley; 2017; 123:3015-3021 10.1002/cncr.30699
• Estrogen–progestin use and breast cancer characteristics in lean and overweight postmenopausal women Cite
  Kjartansdottir OJ, Sigurdardottir LG, Olafsdottir EJ, Jonasson JG, Ursin G, Tryggvadottir L. Estrogen–progestin use and breast cancer characteristics in lean and overweight postmenopausal women. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 163:363-373 10.1007/s10549-017-4171-2
• Abstract P5-10-02: African Americans have more aggressive invasive lobular carcinoma subtypes and inferior early outcomes: SEER 2010-2013 Cite
  Thomas A, Altekruse S, Avery T, Melin S, Howard-McNatt M, Schroeder M. Abstract P5-10-02: African Americans have more aggressive invasive lobular carcinoma subtypes and inferior early outcomes: SEER 2010-2013. Poster Session Abstracts. American Association for Cancer Research; 2017; 10.1158/1538-7445.sabcs16-p5-10-02
• Abstract P2-07-05: Risk of metachronous contralateral breast cancer: Systematic review and meta-analysis Cite
  Akdeniz D, Schmidt M, McCool D, van den Broek A, Hauptmann M, Seynaeve C, et al. Abstract P2-07-05: Risk of metachronous contralateral breast cancer: Systematic review and meta-analysis. Poster Session Abstracts. American Association for Cancer Research; 2017; 10.1158/1538-7445.sabcs16-p2-07-05
• Abstract P1-07-08: Mixed ductal-lobular carcinomas of the breast: Abrogated cell adhesion in the clonal evolution from ductal to lobular morphology Cite
  McCart Reed A, Kutasovic J, Nones K, da Silva L, Melville L, Jayanthan J, et al. Abstract P1-07-08: Mixed ductal-lobular carcinomas of the breast: Abrogated cell adhesion in the clonal evolution from ductal to lobular morphology. Poster Session Abstracts. American Association for Cancer Research; 2017; 10.1158/1538-7445.sabcs16-p1-07-08
• Abstract P1-05-16: An integrated molecular analysis of invasive lobular carcinoma Cite
  Lal S, McCart Reed A, Nones K, Wockner L, Song S, Lakhani S, et al. Abstract P1-05-16: An integrated molecular analysis of invasive lobular carcinoma. Poster Session Abstracts. American Association for Cancer Research; 2017; 10.1158/1538-7445.sabcs16-p1-05-16
• Breast MRI increases the number of mastectomies for ductal cancers, but decreases them for lobular cancers Cite
  Lobbes MB, Vriens IJ, van Bommel AC, Nieuwenhuijzen GA, Smidt ML, Boersma LJ, et al. Breast MRI increases the number of mastectomies for ductal cancers, but decreases them for lobular cancers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 162:353-364 10.1007/s10549-017-4117-8
• Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer Cite
  Inoue M, Nakagomi H, Nakada H, Furuya K, Ikegame K, Watanabe H, et al. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer. Breast Cancer. Springer Science and Business Media LLC; 2017; 24:667-672 10.1007/s12282-017-0753-4
• An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer Cite
  Felts JL, Zhu J, Han B, Smith SJ, Truica CI. An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer. The Breast Journal. Wiley; 2017; 23:677-686 10.1111/tbj.12751
• Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ Cite
  Hwang H, Sahoo S. Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ. A Comprehensive Guide to Core Needle Biopsies of the Breast. Springer International Publishing; 2016;:561-593 10.1007/978-3-319-26291-8_14
• Lobular neoplasia diagnosed on breast Core biopsy: frequency of carcinoma on excision and implications for management Cite
  Calhoun BC, Collie AM, Lott-Limbach AA, Udoji EN, Sieck LR, Booth CN, et al. Lobular neoplasia diagnosed on breast Core biopsy: frequency of carcinoma on excision and implications for management. Annals of Diagnostic Pathology. Elsevier BV; 2016; 25:20-25 10.1016/j.anndiagpath.2016.07.009
• Accuracy of classification of invasive lobular carcinoma on needle core biopsy of the breast: Table 1 Cite
  Naidoo K, Beardsley B, Carder PJ, Deb R, Fish D, Girling A, et al. Accuracy of classification of invasive lobular carcinoma on needle core biopsy of the breast: Table 1. Journal of Clinical Pathology. BMJ; 2016; 69:1122-1123 10.1136/jclinpath-2016-203886
• PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma Cite
  Boelens M, Nethe M, Klarenbeek S, de Ruiter J, Schut E, Bonzanni N, et al. PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma. Cell Reports. Elsevier BV; 2016; 16:2087-2101 10.1016/j.celrep.2016.07.059
• Metastatic pattern of invasive lobular carcinoma of the breast-Emphasis on gastric metastases Cite
  El-Hage A, Ruel C, Afif W, Wissanji H, Hogue J, Desbiens C, et al. Metastatic pattern of invasive lobular carcinoma of the breast-Emphasis on gastric metastases. Journal of Surgical Oncology. Wiley; 2016; 114:543-547 10.1002/jso.24362
• Clinicopathologic Features of Pleomorphic Invasive Lobular Carcinoma: Comparison with Classic Invasive Lobular Carcinoma Cite
  Yeom C, Kim H, Kwon S, Kang SH. Clinicopathologic Features of Pleomorphic Invasive Lobular Carcinoma: Comparison with Classic Invasive Lobular Carcinoma. Journal of Breast Disease. Korean Breast Cancer Society; 2016; 4:10-15 10.14449/jbd.2016.4.1.10
• Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis Cite
  Di Meglio A, Freedman RA, Lin NU, Barry WT, Metzger-Filho O, Keating NL, et al. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 157:587-596 10.1007/s10549-016-3845-5
• Neoadjuvant chemotherapy in breast-conserving surgery – Consequences on margin status and excision volumes Cite
  Volders J, Haloua M, Krekel N, Negenborn V, Barbé E, Sietses C, et al. Neoadjuvant chemotherapy in breast-conserving surgery – Consequences on margin status and excision volumes. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2016; 42:986-993 10.1016/j.ejso.2016.02.252
• Does preoperative breast MRI significantly impact on initial surgical procedure and re-operation rates in patients with screen-detected invasive lobular carcinoma? Cite
  Sinclair K, Sakellariou S, Dawson N, Litherland J. Does preoperative breast MRI significantly impact on initial surgical procedure and re-operation rates in patients with screen-detected invasive lobular carcinoma?. Clinical Radiology. Elsevier BV; 2016; 71:543-550 10.1016/j.crad.2016.03.011
• Sentinel Lymph Node Biopsy and Isolated Tumor Cells in Invasive Lobular Versus Ductal Breast Cancer Cite
  Truin W, Roumen RM, Siesling S, van der Heiden-van der Loo M, Lobbezoo DJ, Tjan-Heijnen VC, et al. Sentinel Lymph Node Biopsy and Isolated Tumor Cells in Invasive Lobular Versus Ductal Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2016; 16:e75-e82 10.1016/j.clbc.2016.03.007
• Another Breast Cancer Entity Confirmed: Genomics of Invasive Lobular Breast Cancer Cite
  Gatza ML, Carey LA. Another Breast Cancer Entity Confirmed: Genomics of Invasive Lobular Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:1838-1839 10.1200/jco.2015.66.3872
• Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma Cite
  Adachi Y, Ishiguro J, Kotani H, Hisada T, Ichikawa M, Gondo N, et al. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma. BMC Cancer. Springer Science and Business Media LLC; 2016; 16 10.1186/s12885-016-2275-4
• Breastfeeding and Immunohistochemical Expression of ki-67, p53 and BCL2 in Infiltrating Lobular Breast Carcinoma Cite
  Gonzalez-Sistal A, Baltasar-Sánchez A, Menéndez P, Arias JI, Ruibal Á. Breastfeeding and Immunohistochemical Expression of ki-67, p53 and BCL2 in Infiltrating Lobular Breast Carcinoma. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0151093 10.1371/journal.pone.0151093
• Genomic Characterization of Primary Invasive Lobular Breast Cancer Cite
  Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, et al. Genomic Characterization of Primary Invasive Lobular Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:1872-1881 10.1200/jco.2015.64.0334
• Breast MRI in Invasive Lobular Carcinoma: A Useful Investigation in Surgical Planning? Cite
  Parvaiz MA, Yang P, Razia E, Mascarenhas M, Deacon C, Matey P, et al. Breast MRI in Invasive Lobular Carcinoma: A Useful Investigation in Surgical Planning?. The Breast Journal. Wiley; 2016; 22:143-150 10.1111/tbj.12566
• Alcohol and breast cancer tumor subtypes in a Spanish Cohort Cite
  Gago-Dominguez M, Castelao JE, Gude F, Fernandez MP, Aguado-Barrera ME, Ponte SM, et al. Alcohol and breast cancer tumor subtypes in a Spanish Cohort. SpringerPlus. Springer Science and Business Media LLC; 2016; 5 10.1186/s40064-015-1630-2
• Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer Cite
  Michaut M, Chin S, Majewski I, Severson TM, Bismeijer T, de Koning L, et al. Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Scientific Reports. Springer Science and Business Media LLC; 2016; 6 10.1038/srep18517
• Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction Cite
  Raghav K, French JT, Ueno NT, Lei X, Krishnamurthy S, Reuben JM, et al. Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0145534 10.1371/journal.pone.0145534
• High Prevalence of MRI-Detected Contralateral and Ipsilateral Malignant Findings in Patients With Invasive Ductolobular Breast Cancer: Impact on Surgical Management Cite
  El Sharouni M, Postma EL, Menezes GL, van den Bosch MA, Pijnappel RM, Witkamp AJ, et al. High Prevalence of MRI-Detected Contralateral and Ipsilateral Malignant Findings in Patients With Invasive Ductolobular Breast Cancer: Impact on Surgical Management. Clinical Breast Cancer. Elsevier BV; 2016; 16:269-275 10.1016/j.clbc.2015.10.002
• The prognostic value of age for invasive lobular breast cancer depending on estrogen receptor and progesterone receptor-defined subtypes: A NCDB analysis Cite
  Liu J, Chen K, Mao K, Su F, Liu Q, Jacobs LK. The prognostic value of age for invasive lobular breast cancer depending on estrogen receptor and progesterone receptor-defined subtypes: A NCDB analysis. Oncotarget. Impact Journals, LLC; 2015; 7:6063-6073 10.18632/oncotarget.5844
• Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer Cite
  Ciriello G, Gatza M, Beck A, Wilkerson M, Rhie S, Pastore A, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. Elsevier BV; 2015; 163:506-519 10.1016/j.cell.2015.09.033
• Is there an association between invasive lobular carcinoma of the breast and a family history of gastric cancer? Cite
  Chikman B, Davidson T, Kais H, Jeroukhimov I, Leshno A, Sandbank J, et al. Is there an association between invasive lobular carcinoma of the breast and a family history of gastric cancer?. Familial Cancer. Springer Science and Business Media LLC; 2015; 15:41-47 10.1007/s10689-015-9833-9
• Fine Needle Aspiration Cytology of Lobular Breast Carcinoma and Its Variants Cite
  Mucha Dufloth R, Xavier-Júnior JCC, Moraes Neto FA, Janoti dos Santos K, Schmitt F. Fine Needle Aspiration Cytology of Lobular Breast Carcinoma and Its Variants. Acta Cytologica. S. Karger AG; 2015; 59:37-42 10.1159/000370211
• Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells Cite
  van Agthoven T, Dorssers LCJ, Lehmann U, Kreipe H, Looijenga LHJ, Christgen M. Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0136845 10.1371/journal.pone.0136845
• Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial Cite
  Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, et al. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015; 33:2772-2779 10.1200/jco.2015.60.8133
• Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study Cite
  Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Joensuu H, et al. Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study. Acta Oncologica. Informa UK Limited; 2015; 55:188-192 10.3109/0284186x.2015.1062538
• Lobular breast cancer: incidence and genetic and non-genetic risk factors Cite
  Dossus L, Benusiglio PR. Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Research. Springer Science and Business Media LLC; 2015; 17 10.1186/s13058-015-0546-7
• Bra Wearing Not Associated with Breast Cancer Risk: A Population-Based Case–Control Study Cite
  Chen L, Malone KE, Li CI. Bra Wearing Not Associated with Breast Cancer Risk: A Population-Based Case–Control Study. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2014; 23:2181-2185 10.1158/1055-9965.epi-14-0414
• Alcohol and Risk of Breast Cancer in Postmenopausal Women: An Analysis of Etiological Heterogeneity by Multiple Tumor Characteristics Cite
  Falk RT, Maas P, Schairer C, Chatterjee N, Mabie JE, Cunningham C, et al. Alcohol and Risk of Breast Cancer in Postmenopausal Women: An Analysis of Etiological Heterogeneity by Multiple Tumor Characteristics. American Journal of Epidemiology. Oxford University Press (OUP); 2014; 180:705-717 10.1093/aje/kwu189
• Synchronous lobular carcinoma in situ and invasive lobular cancer: Marker or precursor for invasive lobular carcinoma Cite
  Wallace A, Xiang D, Hockman L, Arya M, Jeffress J, Wang Z, et al. Synchronous lobular carcinoma in situ and invasive lobular cancer: Marker or precursor for invasive lobular carcinoma. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2014; 40:1245-1249 10.1016/j.ejso.2014.04.007
• Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast Cite
  Sawyer E, Roylance R, Petridis C, Brook MN, Nowinski S, Papouli E, et al. Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics. Public Library of Science (PLoS); 2014; 10:e1004285 10.1371/journal.pgen.1004285
• A Clinicopathological Study of Early-Stage Synchronous Bilateral Breast Cancer: A Retrospective Evaluation and Prospective Validation of Potential Risk Factors Cite
  Chen J, Wang Y, Xue J, Chen Y, Chen Y, Xiao Q, et al. A Clinicopathological Study of Early-Stage Synchronous Bilateral Breast Cancer: A Retrospective Evaluation and Prospective Validation of Potential Risk Factors. PLoS ONE. Public Library of Science (PLoS); 2014; 9:e95185 10.1371/journal.pone.0095185
• The sensitivity of pre-operative axillary staging in breast cancer: Comparison of invasive lobular and ductal carcinoma Cite
  Topps A, Clay V, Absar M, Howe M, Lim Y, Johnson R, et al. The sensitivity of pre-operative axillary staging in breast cancer: Comparison of invasive lobular and ductal carcinoma. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2014; 40:813-817 10.1016/j.ejso.2014.03.026
• Evolving concepts in breast lobular neoplasia and invasive lobular carcinoma, and their impact on imaging methods Cite
  Oliveira TMG, Elias J, Melo AF, Teixeira SR, Filho SC, Gonçalves LM, et al. Evolving concepts in breast lobular neoplasia and invasive lobular carcinoma, and their impact on imaging methods. Insights into Imaging. Springer Science and Business Media LLC; 2014; 5:183-194 10.1007/s13244-014-0324-6
• Prognostic implications of lobular breast cancer histology: New insights from a single hospital cross-sectional study and SEER data Cite
  Brouckaert O, Laenen A, Smeets A, Christiaens M, Vergote I, Wildiers H, et al. Prognostic implications of lobular breast cancer histology: New insights from a single hospital cross-sectional study and SEER data. The Breast. Elsevier BV; 2014; 23:371-377 10.1016/j.breast.2014.01.007
• Outcomes of Sentinel Lymph Node Dissection Alone vs. Axillary Lymph Node Dissection in Early Stage Invasive Lobular Carcinoma: A Retrospective Study of the Surveillance, Epidemiology and End Results (SEER) Database Cite
  Wang J, Mittendorf EA, Sahin AA, Yi M, Caudle A, Hunt KK, et al. Outcomes of Sentinel Lymph Node Dissection Alone vs. Axillary Lymph Node Dissection in Early Stage Invasive Lobular Carcinoma: A Retrospective Study of the Surveillance, Epidemiology and End Results (SEER) Database. PLoS ONE. Public Library of Science (PLoS); 2014; 9:e89778 10.1371/journal.pone.0089778
• Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor Cite
  Narbe U, Bendahl P, Grabau D, Rydén L, Ingvar C, Fernö M. Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor. SpringerPlus. Springer Science and Business Media LLC; 2014; 3 10.1186/2193-1801-3-70
• Risk of Local Failure in Breast Cancer Patients With Lobular Carcinoma In Situ at the Final Surgical Margins: Is Re-excision Necessary? Cite
  Sadek BT, Shenouda MN, Abi Raad RF, Niemierko A, Keruakous AR, Goldberg SI, et al. Risk of Local Failure in Breast Cancer Patients With Lobular Carcinoma In Situ at the Final Surgical Margins: Is Re-excision Necessary?. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2013; 87:726-730 10.1016/j.ijrobp.2013.08.012
• Use of Antihypertensive Medications and Breast Cancer Risk Among Women Aged 55 to 74 Years Cite
  Li CI, Daling JR, Tang MC, Haugen KL, Porter PL, Malone KE. Use of Antihypertensive Medications and Breast Cancer Risk Among Women Aged 55 to 74 Years. JAMA Internal Medicine. American Medical Association (AMA); 2013; 173:1629 10.1001/jamainternmed.2013.9071
• The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients Cite
  Korhonen T, Kuukasjärvi T, Huhtala H, Alarmo E, Holli K, Kallioniemi A, et al. The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients. The Breast. Elsevier BV; 2013; 22:1119-1124 10.1016/j.breast.2013.06.001
• Long-Term Statin Use and Risk of Ductal and Lobular Breast Cancer among Women 55 to 74 Years of Age Cite
  McDougall JA, Malone KE, Daling JR, Cushing-Haugen KL, Porter PL, Li CI. Long-Term Statin Use and Risk of Ductal and Lobular Breast Cancer among Women 55 to 74 Years of Age. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2013; 22:1529-1537 10.1158/1055-9965.epi-13-0414
• Risk Factors for Specific Histopathological Types of Postmenopausal Breast Cancer in the NIH-AARP Diet and Health Study Cite
  Nyante SJ, Dallal CM, Gierach GL, Park Y, Hollenbeck AR, Brinton LA. Risk Factors for Specific Histopathological Types of Postmenopausal Breast Cancer in the NIH-AARP Diet and Health Study. American Journal of Epidemiology. Oxford University Press (OUP); 2013; 178:359-371 10.1093/aje/kws471
• Mammographic and ultrasound features of invasive lobular carcinoma of the breast Cite
  Porter AJ, Evans EB, Foxcroft LM, Simpson PT, Lakhani SR. Mammographic and ultrasound features of invasive lobular carcinoma of the breast. Journal of Medical Imaging and Radiation Oncology. Wiley; 2013; 58:1-10 10.1111/1754-9485.12080
• Invasive lobular carcinoma of the breast: Patient response to systemic endocrine therapy and hormone response in model systems Cite
  Sikora MJ, Jankowitz RC, Dabbs DJ, Oesterreich S. Invasive lobular carcinoma of the breast: Patient response to systemic endocrine therapy and hormone response in model systems. Steroids. Elsevier BV; 2013; 78:568-575 10.1016/j.steroids.2012.11.002
• Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies Cite
  Collaborative Group on Hormonal Factors in Breast Cancer . Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. The Lancet Oncology. Elsevier BV; 2012; 13:1141-1151 10.1016/s1470-2045(12)70425-4
• Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome Cite
  Montagna E, Maisonneuve P, Rotmensz N, Cancello G, Iorfida M, Balduzzi A, et al. Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome. Clinical Breast Cancer. Elsevier BV; 2013; 13:31-39 10.1016/j.clbc.2012.09.002
• Invasive Pleomorphic Lobular Carcinoma of the Breast: Clinicopathologic Characteristics and Prognosis Compared with Invasive Ductal Carcinoma Cite
  Jung SP, Lee SK, Kim S, Choi M, Bae SY, Kim J, et al. Invasive Pleomorphic Lobular Carcinoma of the Breast: Clinicopathologic Characteristics and Prognosis Compared with Invasive Ductal Carcinoma. Journal of Breast Cancer. Korean Breast Cancer Society; 2012; 15:313 10.4048/jbc.2012.15.3.313
• Hormone Therapy Use and Breast Cancer Incidence by Histological Subtypes in Sweden and Norway Cite
  Suhrke P, Maehlen J, Zahl P. Hormone Therapy Use and Breast Cancer Incidence by Histological Subtypes in Sweden and Norway. The Breast Journal. Wiley; 2012; 18:549-556 10.1111/tbj.12001
• The Significance of Lobular Carcinoma In Situ and Atypical Lobular Hyperplasia of the Breast Cite
  Lewis JL, Lee DY, Tartter PI. The Significance of Lobular Carcinoma In Situ and Atypical Lobular Hyperplasia of the Breast. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2012; 19:4124-4128 10.1245/s10434-012-2538-5
• Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions Cite
  Andrade VP, Ostrovnaya I, Seshan VE, Morrogh M, Giri D, Olvera N, et al. Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Research. Springer Science and Business Media LLC; 2012; 14 10.1186/bcr3222
• Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer Cite
  Truin W, Voogd A, Vreugdenhil G, van der Heiden-van der Loo M, Siesling S, Roumen R. Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer. Annals of Oncology. Elsevier BV; 2012; 23:2859-2865 10.1093/annonc/mds180
• Invasive lobular (ILC) versus invasive ductal (IDC) breast cancer (BC): Clinical-pathologic features and clinical outcomes in monoinstitutional series. Cite
  Ferro A, Eccher C, Caldara A, Triolo R, Barbareschi M, Cuorvo LV, et al. Invasive lobular (ILC) versus invasive ductal (IDC) breast cancer (BC): Clinical-pathologic features and clinical outcomes in monoinstitutional series.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:e21102-e21102 10.1200/jco.2012.30.15_suppl.e21102
• Response pattern in 844 patients with infiltrating lobular carcinoma (ILC) of the breast after neoadjuvant chemotherapy. Cite
  Pirvulescu C, Loibl S, Von Minckwitz G, Mau C, Blohmer JU, Costa SD, et al. Response pattern in 844 patients with infiltrating lobular carcinoma (ILC) of the breast after neoadjuvant chemotherapy.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:541-541 10.1200/jco.2012.30.15_suppl.541
• Nonsurgical Management of High-Risk Lesions Diagnosed at Core Needle Biopsy: Can Malignancy Be Ruled Out Safely With Breast MRI? Cite
  Linda A, Zuiani C, Furlan A, Lorenzon M, Londero V, Girometti R, et al. Nonsurgical Management of High-Risk Lesions Diagnosed at Core Needle Biopsy: Can Malignancy Be Ruled Out Safely With Breast MRI?. American Journal of Roentgenology. American Roentgen Ray Society; 2012; 198:272-280 10.2214/ajr.11.7040
• Surgical Outcome of Biopsy-Proven Lobular Neoplasia: Is There Any Difference Between Lobular Carcinoma In Situ and Atypical Lobular Hyperplasia? Cite
  Ibrahim N, Bessissow A, Lalonde L, Mesurolle B, Trop I, Lisbona A, et al. Surgical Outcome of Biopsy-Proven Lobular Neoplasia: Is There Any Difference Between Lobular Carcinoma In Situ and Atypical Lobular Hyperplasia?. American Journal of Roentgenology. American Roentgen Ray Society; 2012; 198:288-291 10.2214/ajr.11.7212
• Invasive lobular breast cancer: subtypes and outcome Cite
  Iorfida M, Maiorano E, Orvieto E, Maisonneuve P, Bottiglieri L, Rotmensz N, et al. Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 133:713-723 10.1007/s10549-012-2002-z
• Low Frequency of Cancer Occurrence in Same Breast Quadrant Diagnosed with Lobular Neoplasia at Percutaneous Needle Biopsy Cite
  Provencher L, Jacob S, Côté G, Hogue J, Desbiens C, Poirier B, et al. Low Frequency of Cancer Occurrence in Same Breast Quadrant Diagnosed with Lobular Neoplasia at Percutaneous Needle Biopsy. Radiology. Radiological Society of North America (RSNA); 2012; 263:43-52 10.1148/radiol.11111293
• Accelerated partial breast irradiation using once-daily fractionation: analysis of 312 cases with four years median follow-up Cite
  Shaikh AY, LaCombe MA, Du H, Raghavan VT, Nanda RK, Bloomer WD. Accelerated partial breast irradiation using once-daily fractionation: analysis of 312 cases with four years median follow-up. Radiation Oncology. Springer Science and Business Media LLC; 2012; 7 10.1186/1748-717x-7-17
• Influence of uncommon histology on breast conservation therapy for breast cancer-biology dictates technique? Cite
  Wasif N, McCullough AE, Gray RJ, Pockaj BA. Influence of uncommon histology on breast conservation therapy for breast cancer-biology dictates technique?. Journal of Surgical Oncology. Wiley; 2011; 105:586-590 10.1002/jso.22132
• Outcome of special types of luminal breast cancer Cite
  Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua M, Luini A, Veronesi P, et al. Outcome of special types of luminal breast cancer. Annals of Oncology. Elsevier BV; 2012; 23:1428-1436 10.1093/annonc/mdr461
• Association between race and BMI with response to neoadjuvant endocrine therapy in postmenopausal women with large estrogen receptor-positive breast cancers. Cite
  Ambros T, Sujoy V, Fernandez CG, Reis I, Wright JL, Jorda M, et al. Association between race and BMI with response to neoadjuvant endocrine therapy in postmenopausal women with large estrogen receptor-positive breast cancers.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:132-132 10.1200/jco.2011.29.27_suppl.132
• Lobular Breast Cancer: Same Survival and Local Control Compared with Ductal Cancer, but Should Both Be Treated the Same Way? Analysis of an Institutional Database over a 10-Year Period Cite
  Fortunato L, Mascaro A, Poccia I, Andrich R, Amini M, Costarelli L, et al. Lobular Breast Cancer: Same Survival and Local Control Compared with Ductal Cancer, but Should Both Be Treated the Same Way? Analysis of an Institutional Database over a 10-Year Period. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2011; 19:1107-1114 10.1245/s10434-011-1907-9
• Lobular neoplasia on core biopsy: Is excision always indicated? Cite
  Makarewich CA, Rosenkranz KM. Lobular neoplasia on core biopsy: Is excision always indicated?. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:75-75 10.1200/jco.2011.29.27_suppl.75
• Invasive lobular carcinoma: response to neoadjuvant letrozole therapy Cite
  Dixon JM, Renshaw L, Dixon J, Thomas J. Invasive lobular carcinoma: response to neoadjuvant letrozole therapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 130:871-877 10.1007/s10549-011-1735-4
• Neoadjuvant Chemotherapy Increases the Rate of Breast Conservation in Lobular-Type Breast Cancer Patients Cite
  Fitzal F, Mittlboeck M, Steger G, Bartsch R, Rudas M, Dubsky P, et al. Neoadjuvant Chemotherapy Increases the Rate of Breast Conservation in Lobular-Type Breast Cancer Patients. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2011; 19:519-526 10.1245/s10434-011-1879-9
• Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast Cite
  Fernandez B, Paish EC, Green AR, Lee AHS, Macmillan RD, Ellis IO, et al. Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast. Journal of Clinical Pathology. BMJ; 2011; 64:995-1000 10.1136/jclinpath-2011-200151
• Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer Cite
  Truin W, Voogd AC, Vreugdenhil G, van der Sangen MJ, van Beek MW, Roumen RM. Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer. The Breast. Elsevier BV; 2011; 20:505-509 10.1016/j.breast.2011.05.005
• Clear margins for invasive lobular carcinoma: A surgical challenge Cite
  Sakr R, Poulet B, Kaufman G, Nos C, Clough K. Clear margins for invasive lobular carcinoma: A surgical challenge. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2011; 37:350-356 10.1016/j.ejso.2011.01.010
• Do patients with invasive lobular breast cancer benefit in terms of adequate change in surgical therapy from a supplementary preoperative breast MRI? Cite
  Heil J, Buehler A, Golatta M, Rom J, Schipp A, Harcos A, et al. Do patients with invasive lobular breast cancer benefit in terms of adequate change in surgical therapy from a supplementary preoperative breast MRI?. Annals of Oncology. Elsevier BV; 2012; 23:98-104 10.1093/annonc/mdr064
• Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast–A review Cite
  Hussain M, Cunnick G. Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast–A review. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2011; 37:279-289 10.1016/j.ejso.2011.01.009
• Relationship between Menopausal Symptoms and Risk of Postmenopausal Breast Cancer Cite
  Huang Y, Malone KE, Cushing-Haugen KL, Daling JR, Li CI. Relationship between Menopausal Symptoms and Risk of Postmenopausal Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2011; 20:379-388 10.1158/1055-9965.epi-10-0998
• Role of MRI (magnetic resonance imaging) versus conventional imaging for breast cancer presurgical staging in young women or with dense breast Cite
  Biglia N, Bounous V, Martincich L, Panuccio E, Liberale V, Ottino L, et al. Role of MRI (magnetic resonance imaging) versus conventional imaging for breast cancer presurgical staging in young women or with dense breast. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2011; 37:199-204 10.1016/j.ejso.2010.12.011
• Effect of the introduction of preoperative MRI scans for lobular cancer in an individual breast unit Cite
  Cain H, Sinclair J, Martin A, Fasih T, Browell D, Clark K, et al. Effect of the introduction of preoperative MRI scans for lobular cancer in an individual breast unit. Breast Cancer Research. Springer Science and Business Media LLC; 2010; 12 10.1186/bcr2680
• Accurate classification of sentinel lymph node metastases in patients with lobular breast carcinoma Cite
  Apple SK, Moatamed NA, Finck RH, Sullivan PS. Accurate classification of sentinel lymph node metastases in patients with lobular breast carcinoma. The Breast. Elsevier BV; 2010; 19:360-364 10.1016/j.breast.2010.02.010
• Alcohol Consumption and Risk of Postmenopausal Breast Cancer by Subtype: The Women's Health Initiative Observational Study Cite
  Li CI, Chlebowski RT, Freiberg M, Johnson KC, Kuller L, Lane D, et al. Alcohol Consumption and Risk of Postmenopausal Breast Cancer by Subtype: The Women's Health Initiative Observational Study. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2010; 102:1422-1431 10.1093/jnci/djq316
• Micronutrient intake and breast cancer characteristics among postmenopausal women Cite
  Roswall N, Olsen A, Christensen J, Dragsted LO, Overvad K, Tjønneland A. Micronutrient intake and breast cancer characteristics among postmenopausal women. European Journal of Cancer Prevention. Ovid Technologies (Wolters Kluwer Health); 2010; 19:360-365 10.1097/cej.0b013e32833ade68
• The impact of young age on breast cancer outcome Cite
  Livi L, Meattini I, Saieva C, Borghesi S, Scotti V, Petrucci A, et al. The impact of young age on breast cancer outcome. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2010; 36:639-645 10.1016/j.ejso.2010.05.016
• Specialty Supplements and Breast Cancer Risk in the VITamins And Lifestyle (VITAL) Cohort Cite
  Brasky TM, Lampe JW, Potter JD, Patterson RE, White E. Specialty Supplements and Breast Cancer Risk in the VITamins And Lifestyle (VITAL) Cohort. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2010; 19:1696-1708 10.1158/1055-9965.epi-10-0318
• Risk Factors for Ductal, Lobular, and Mixed Ductal-Lobular Breast Cancer in a Screening Population Cite
  Phipps AI, Li CI, Kerlikowske K, Barlow WE, Buist DSM. Risk Factors for Ductal, Lobular, and Mixed Ductal-Lobular Breast Cancer in a Screening Population. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2010; 19:1643-1654 10.1158/1055-9965.epi-10-0188
• Two distinct molecular subgroups of lobular carcinoma in situ associated with invasive lobular carcinoma. Cite
  Andrade VP, Morrogh M, Sakr R, Muhsen S, Paik W, Li-Xuan Q, et al. Two distinct molecular subgroups of lobular carcinoma in situ associated with invasive lobular carcinoma.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:e21077-e21077 10.1200/jco.2010.28.15_suppl.e21077
• Characteristics and outcomes of invasive lobular of carcinoma and invasive ductal carcinoma of the breast: SEER/Medicare 1992-2002. Cite
  Thomas A, Xie Y, Wright KB, Brooks J. Characteristics and outcomes of invasive lobular of carcinoma and invasive ductal carcinoma of the breast: SEER/Medicare 1992-2002.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:e16520-e16520 10.1200/jco.2010.28.15_suppl.e16520
• Risk for subsequent breast cancer after lobular carcinoma in situ: Do clinical factors matter? Cite
  Muhsen S, Morrogh M, Andrade AP, Sakr R, Paik W, Morrow M, et al. Risk for subsequent breast cancer after lobular carcinoma in situ: Do clinical factors matter?. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1593-1593 10.1200/jco.2010.28.15_suppl.1593
• Breast cancer patients with lobular cancer more commonly have a father than a mother diagnosed with cancer Cite
  Ellberg C, Olsson H. Breast cancer patients with lobular cancer more commonly have a father than a mother diagnosed with cancer. BMC Cancer. Springer Science and Business Media LLC; 2011; 11 10.1186/1471-2407-11-497
• Conservative surgery in patients with multifocal/multicentric breast cancer Cite
  Gentilini O, Botteri E, Rotmensz N, Da Lima L, Caliskan M, Garcia-Etienne CA, et al. Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2008; 113:577-583 10.1007/s10549-008-9959-7
• Tea Consumption and Risk of Breast Cancer Cite
  Kumar N, Titus-Ernstoff L, Newcomb PA, Trentham-Dietz A, Anic G, Egan KM. Tea Consumption and Risk of Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2009; 18:341-345 10.1158/1055-9965.epi-08-0819